Summary 6-keto-PGFi,, and thromboxane B2 were determined by radioimmunoassay in 37 extracts of breast carcinomata, 8 fibroadenomata, 12 sclerocystic-disease specimens and 51 normal breast tissues. More prostanoids were extracted from carcinomata than from normal specimens, fibroadenomata or sclerocysticdisease tissues (P<0.05). The 6-keto-PGF1./TXB2 ratio was higher in carcinomata than in normal tissues and fibroadenomata (P<0.05) but was not significantly different from the ratio in sclerocystic disease. The prostaglandin levels and the 6-keto-PGF1./TXB2 ratios from carcinomata did not correlate significantly with age, tumour size, differentiation, lymph node status, nuclear-cytoplasmic ratio, host cell reaction, mast cells, necrosis, elastosis, fibrosis or blood vessel density. Lower nuclear density was associated with lower 6-keto-PGF1,/TXB2 ratios (P=0.01) whereas the latter value was higher when infiltration was lower (P=0.03). There was a positive correlation between mitotic index and the 6-keto-PGF1./TXB2 ratio (P=0.04).
PGF1,/TXB2 ratios (P=0.01) whereas the latter value was higher when infiltration was lower (P=0.03). There was a positive correlation between mitotic index and the 6-keto-PGF1./TXB2 ratio (P=0.04).
Cumulation of variables revealed lower prostanoid ratios in tumours >2cm without lymph node metastasis then tumours <2cm with lymph node metastasis (P=0.05). A first follow-up (14 months) showed a higher 6-keto-PGF1./TXB2 ratio in patients who developed metastasis (P=0.04). Our study does not confirm the hypothesis that high prostacyclin levels are a good prognostic index in breast cancer.
Honn et al. (1981) found that prostacyclin (PGI2) had a beneficial influence against metastasis of B16 amelanotic melanoma tumours in mice, whereas inhibitors of PGI2 synthesis enhanced the number of metastases. Other authors tested the antimetastatic potency of acetylsalicylic acid, indomethacin, dipyridamole, flurbiprofen, benorylate, heparin and warfarin (Gasic et al., 1973; Elias et al., 1973; Lione & Bosman, 1978; Bennett, 1982) . Most of these studies are done on animals and showed no clearcut results.
Thromboxane (TX) A2 is often a physiological antagonist of PGI2 and an imbalance between them can disturb the (anti)haemostatic system. The antiaggregating properties of nonsteroidal antiinflammatory drugs (NSAID) can be explained by a stronger inhibition of the platelet cyclo-oxygenase in comparison with that of the vessel wall. As a result the release of TX will be lowered and aggregation will be blocked (Bunting et al., 1983) . Sloane et al. (1981) showed that some tumours are able to release cathepsin B. This enzyme stimulates the synthesis of TX and is produced in a variant of B16 melanoma which has high metastatic activity.
In order to study a possible prognostic value of the PGI2/TX ratio in breast cancer, the stable hydrolysis products of PGI2 (6-keto-PGF1,) and TXA2 (TXB2) were determined by RIA. 6-keto-PGF1, and TXB2 levels were examined in relation to the size of the tumour, axillary lymph node status, lymphatic vessel permeation, differentiation of the tumour, mitotic index density of nuclei of tumour cells, and age of the patient.
PG production can be influenced by inflammatory processes (Humes et al., 1977; Brune et al., 1978) , and therefore the number of host-derived cells and the amount of necrosis was evaluated. Also the density of blood vessels was estimated as they could be a major source of 6-keto-PGF1. (Moncada et al., 1976) , and platelets contribute considerably to the amounts of TXB2 measured (Hamberg et al., 1975) .
Materials and methods
We obtained 108 specimens from 67 patients who underwent surgery for a breast lump. Each specimen was divided into two representative parts and prepared as described earlier by Vergote et al. (1985) . The tissues were immediately immersed either in acetone cooled by solid CO2 (-70°C) for 6-keto-PGF1. or TXB2 analysis, or in Bouin's liquid for histopathological examination. The tissue samples for prostanoid investigation were stored at -30°C until radioimmunoassay was performed. Thirty-five tumours were diagnosed as primary breast cancer (patient age range: 36-82; mean 64). The patients were classified according to the pathological TNM system (UICC, Livre de Poche), pTlaNo 9; pTlaNla 1; pTlaNlb 4; pTlaNx 2; pT2aNo 4; pT2aNla 2; pT2aNlb 4; pT2aNx 2; pT3aNo 2; pT4bNx 1. No patient had overt metastases at the time of surgery and none was under current treatment with non-steroidal inflammatory drugs or corticosteroids. Five local relapses (ductal carcinomata) and one cellular intracanicular fibroadenoma were included. Twenty tumours were benign: 8 fibroadenomata (age range: 17-47, mean: 34) and 12 sclerocystic-disease specimens (age range: 37-70, mean: 49). We investigated also histologically confirmed normal breast tissue of patients with malignant tumours and fibroadenomata. Furthermore, 12 specimens of patients who had neither benign nor malignant tumours were studied. The age of the patients and the tumour size at anatomopathological examination were recorded.
The amounts of 6-keto-PGF1. and TXB2 were expressed as ngmg-1 protein and from these values the 6-keto-PGF1./TXB2 ratio was calculated.
Histopathology
The slides were independently reviewed by two of the authors and re-evaluated by a senior pathologist. In case of discordance, the results were not included in this study.
Tumours were classified according to the methodology used earlier (Vergote et al., 1985) . Subdivision of histopathological variables is shown in Table III Granstrom and Kindahl (1978) . The antisera were raised in rabbits. Cross reactivities on the 50% binding level of the curve were: for the 6-keto-PGF1. Sokal & Rohlf, 1981) . Correlation coefficients were calculated by linear regression.
Results
PG levels in relation to the histopathological groups 6-keto-PGF1a levels were higher in carcinomata (CA) than in normal breast tissue (N), fibroadenomata (FA) and sclerocystic disease (SCD) (P=0.0003, Kruskal & Wallis). In FA, N and SCD the levels did not differ significantly (P = 0.17, Kruskal & Wallis). CA-TXB2 levels were significantly higher in comparison with the other groups (P = 0.05, Kruskal & Wallis). The differences between N, FA and SCD were not significant (P = 0.83, Kruskal & Wallis). The 6-keto-PGF1J/TXB2 ratio in CA was higher than in N and FA (P= 0.002, Kruskal & Wallis) which were similar (P= 0.39). SCD and CA also gave similar ratios (P= 0.67). These results are summarized in Table I and Figure  1 . When local relapses (n=5) were calculated separately, 6-keto-PGF1,, TXB2 and the 6-keto-PGF1./TXB2 ratio were respectively, median (limit values): 12.7 (0.6-15.0) ngmg-1 protein, 2.5 (1.8-3.4) ngmg-1 protein and 4.0 (0.3-7.3). They were similar to the ductal carcinomata (P= 0.95; P= 0.40 and P=0.28 respectively).
Histological type and differentiation The infiltrating ductal carcinomata composed the substantial group. Statistical comparison between all the groups was difficult because some contained very few cases (Table II) . We divided the tumours into two groups: undifferentiated and some degree of differentiation (small, noderate or high). Both groups showed similar 6-keto-PGF1,, TXB2 and 6-keto-PGF1./TXB2 levels (Table III) .
Lymph node metastasis and lymphatic vessel permeation
The median amount of 6-keto-PGF1a was slightly higher in tumour extracts from patients without lymph node metastasis (P= 0.23). Median TXB2 amounts and the 6-keto-PGF1a/TXB2 ratio were comparable. The groups without lymphatic vessel permeation had more 6-keto-PGF1a (P=0.04), but the TXB2 values and the 6-keto-PGF1./TXB2 ratio were similar (Table III) . inversely related to the 6-keto-PGFJT/TXB2 ratio (P=0.03), but no significant differences were seen for the 6-keto-PGF1. or TXB2 (Table III) .
Blood vessel density
Presence of blood vessels did not correlate with prostanoid yields in the tumour biopsies. the 6-keto-PGF1./TXB2 ratio even tended to be lower when more blood vessels were present (P = 0.18; Table III PGFJ./TXB2 r= -0.038 (P=0.42). Tumours with strong metastatic potential (<2cm and lymph node metastasis, n=5) had a median 6-keto-PGF1,/TXB2 ratio of 3.8 (2.0-9.4), which was higher (P <0.05) than with tumours having a relatively weak metastatic potential (>2 cm and no lymph node metastasis, n = 7; 2.8 (0.5-4,6)).
A preliminary analysis of 19 patients with a follow-up of 14 months revealed metastases in 5 patients. These 5 patients had a median 6-keto-PGF,,/TXB2 ratio of 9.2 (4.0-15.3) which was higher than the ratio of nonmetastatic patients 4.8 (1.6-13.5) (P=0.04).
Discussion
Little is known about the role of PGI2 and TX in human malignant tumours, and only 2 studies on extracted breast tissues have been published. Karmali et al. (1983) measured 6-keto-PGF1. and TXB2 in 24 breast tumours and expressed their results as log ng g-1 wet weight. They obtained more TXB2 from large tumours and those with lymph node metastasis. These results were interpreted as supporting the findings of Honn (1981) that a higher TXA2/PGI2 ratio has a worse prognosis in terms of metastasis.
However, Karmali et al. (1983) did not give any data about the 6-keto-PGF1./TXB2 ratio which is important in the regulation of blood platelet aggregation. Furthermore, the size of the tumour is not necessarily an indication of the metastatic potential. In addition, Karmali et al. (1983) observed no correlation between TXB2 levels and metastasis. Aitokallio-Tallberg et al. (1985) studied the in vitro production of 6-keto-PGF1, and TXB2 by 23 breast tumour tissues, but as their investigations were directed towards steroid receptor status (14) high (14) Blood vessel density low (14) moderate (8) high ( they did not include control tissue superfusion in their protocol. The prostanoid yields were similar from metastatized and non-metastatized cancers (follow-up of at least 3 years).
We studied the PG-levels in the tumours at the time of resection. Treatment with acetone at -70°C inactivated the tumour enzymes and stopped the conversion of arachidonic acid to prostaglandins (Vergote et al., 1985) . Prostanoids were measured in the tumour extracts, but the recoveries were about 100%, we can consider the RIA-results as reflecting the prostanoid production at the time of resection. Since the surgical manipulation might induce PGI2 and TXA2 production, we also analyzed normal breast tissue taken from the neighbourhood of the cancer. The tumour specimen was always taken first, so that artefactual prostanoid might be higher in the normal tissue because of the longer trauma or lower because of prostanoid metabolism. For example 6,15-diketo 13,14-dihydro PGF,, is formed from PGI2 in plasma and vascular tissue (Peskar et al., 1980) . However, continued enzymatic conversion would be blocked by the acetone treatment.
Non-malignant sources of the tumour prostanoids are the host cells, but no correlation was found between the amounts of the prostanoids and the host cell reaction or the presence of mast cells.
Furthermore, the 6-keto-PGFJ and TXB2 tissue levels did not correlate with the density of blood vessels.
We preferred to express the prostanoid yields in ng mg1 protein, rather than to use ng g-wet or dry weight, in an attempt to reduce the variation of the results. One of the main conclusions from our study is that carcinomata had higher median 6-keto-PGF1. and TXB2 levels than N, FA or SCD, but even so, the ranges overlapped considerably.
As can be seen from Table III , most of the differences were not significant, but a high metastatic potential and mitotic index correlated with higher 6-keto-PGF1J/TXB2 ratios. Furthermore, with 42 comparisons, 2 would be expected by chance to show P values <0.05 when no difference really exists.
No firm conclusions can yet be made, although follow-up over 14 months revealed a higher 6-keto-PGFJ,/TXB2 ratio in patients with metastasis.
These data should be interpreted very cautiously, as the number of patients evaluated is low and the follow-up period is limited. Nevertheless, the histopathology results do not support the suggestion of Karmali et al. (1983) , for a protective action of prostacyclin against metastasis in human breast cancer, or the hypothesis of Honn (1981) that TXA2 promotes metastasis.
A common observation by several authors is the greater prostaglandin production by malignant breast tumours compared with normal breast tissues. This conclusion is independent of the prostaglandin measured or the ways of performitig the incubations, extractions or measurements (Bennett et al., 1975; Kibbey et al., 1979; Greaves et al., 1980; Rolland et al., 1980; Malachi et al., 1981; Campbell et al., 1983; Karmali et al., 1983) . The relationship between high prostaglandin levels and malignancy of breast tumours could lead to the systematic incorporation of cyclo-oxygenase inhibitors (NSAID) in cancer therapy. However, when histopathological prognostic variables of malignant tissues are examined, the prognosis seems to be better when the PGF2a levels were higher (Vergote et al., 1985) . Although this was not found for 6-keto-PGF1 and TXB2 in our present study, the mitotic index, prognosis and the first follow-up results indicate that tumour 6-keto-PGF1 at the time of surgery was often higher in patients with bad prognosis or metastasis. Using NSAID could theoretically worsen the prognosis, by depressing the 6-keto-PGF1. levels, but we do not know what effect this would have on the 6-keto-PGFJ,/TXB2 ratio. Therefore we can neither support nor recommend the use of NSAID in the treatment of breast cancer, particularly since other actions of prostaglandins, e.g. in immunological functions, may also be affected.
